Search

Displaying results 6401 - 6410 of 10000 in total
  1. Drug

    Nigericin

    go.drugbank.com/drugs/DB14056
    Experimental

    It is produced by Streptomyces hygroscopicus. (From Merck Index, 11th ed)

  2. Drug

    REC-994

    go.drugbank.com/drugs/DB15616
    Investigational

    REC-994 was cleared by the FDA in July, 2018 for a phase I trial for the treatment of cerebral cavernous malformation (CCM).

  3. Drug

    Autologous Hematopoietic Peripheral Blood Stem Cells

    go.drugbank.com/drugs/DB17067
    Investigational

    Autologous hematopoietic peripheral blood stem cells were tested in a clinical trial (NCT00424489) by Northwestern University for the treatment of refractory myasthenia gravis.

  4. Drug

    CP-122721

    go.drugbank.com/drugs/DB05421
    Experimental

    CP-122721, neurokinin 1 (NK1) antagonist is developed by Pfizer to treat depression, emesis, and inflammatory diseases including asthma and irritable bowel syndrome.

  5. Indication

    Breast Infection

    go.drugbank.com/conditions/DBCOND0057784
    Drugs: Josamycin
    Synonyms: Mastitis, NOS, Breast infection NOS
  6. Indication

    Secondary Thrombocytopenia

    go.drugbank.com/conditions/DBCOND0021268
    Drugs: Betamethasone · Bupivacaine · Cortisone acetate · Dexamethasone · Hydrocortisone · Hydrocortisone succinate +5 more
    Synonyms: Thrombocytopenia NOS, Thrombocytopenia, NOS
  7. Drug

    Sodium ferric gluconate complex

    go.drugbank.com/drugs/DB09517
    Approved

    Sodium ferric gluconate complex is an iron replacement product for treatment of iron deficiency anemia. The stable macromolecular complex is negatively charged at alkaline pH with an apparent molecular weight of 289,000 – 440,000 daltons...

  8. Drug

    VaxSyn

    go.drugbank.com/drugs/DB17827
    Investigational

    VaxSyn HIV-1 is a recombinant form of the HIV envelope protein gp 160 developed by MicroGeneSys and the National Institute of Allergy and Infectious Diseases (NIAID).

  9. Drug

    ENTR-601-44

    go.drugbank.com/drugs/DB17836
    Investigational

    Developed by Entrada Therapeutics, it was investigated for the treatment of Duchenne muscular dystrophy.[L46641]

  10. Drug

    PAS-004

    go.drugbank.com/drugs/DB18611
    Investigational

    PAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome.